| Original language | English (US) |
|---|---|
| Pages (from-to) | 779-784 |
| Number of pages | 6 |
| Journal | Academic Psychiatry |
| Volume | 44 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 2020 |
ASJC Scopus subject areas
- Education
- Psychiatry and Mental health
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Academic Psychiatry, Vol. 44, No. 6, 12.2020, p. 779-784.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - The Psychiatry Milestones 2.0
T2 - How Did We Get from 1.0 to 2.0 and What Can Users Expect?
AU - Macaluso, Matthew
AU - Kinzie, Mark
AU - Cowley, Deborah
AU - Houston, Lillian J.
AU - DeJong, Sandra
AU - Janssen, Furhut
AU - Bentman, Adrienne
AU - Edgar, Laura
AU - Campbell, Brittany
AU - Bowen, Lynneice
AU - Aronowitz, Jeffery
AU - Aoun, Elie
AU - Santiago, Patcho
AU - Keepers, George
N1 - Funding Information: Jeffrey Aronowitz, D.O., was funded by the ACGME to travel to Milestones 2.0 Working Group Meetings. Adrienne Bentman, M.D., is serving a term as Vice-Chair of the ACGME Psychiatry Review Committee from 2020 to 2022. Lynneice Bowen, M.D., reports non-financial support from the ACGME during her participation on the Milestones 2.0 Working Group. Deborah Cowley, M.D., was funded by the ACGME to travel to Milestones 2.0 Working Group Meetings. Sandra DeJong, M.D., was funded by the ACGME to travel to Milestones 2.0 Working Group Meetings. Lillian Houston, M.D., reports non-financial support from the ACGME during her participation on the Milestones 2.0 Working Group. George Keepers, M.D., served on the American Board of Psychiatry and Neurology Board of Directors from 2011 to 2018, the ACGME Psychiatry Residency Review Committee, the ACGME Psychiatry Milestones Task Force 1.0, and the ACGME Psychiatry Milestones Task Force 2.0. Matthew Macaluso, D.O., has conducted clinical trials research as principal investigator for the following pharmaceutical companies over the last twelve months: (1) Acadia, (2) Allergan, (3) Alkermes, (4) AssureRx/Myriad, (5) Eisai, (6) Lundbeck, (7) Janssen, (8) Neurim, (9) SAGE pharmaceuticals, (10) Suven. All clinical trial and study contracts were with and payments made to the Kansas University Medical Center Research Institute, a research institute affiliated with Kansas University School of Medicine Wichita (KUSM-W). Dr. Macaluso is also a member of the speaker bureau for Janssen pharmaceuticals (esketamine). Dr. Macaluso does not believe these relationships pose a conflict relative to this work. Funding Information: The authors would like to acknowledge Marisa Jones (the University of Kansas) and Sydney Mclean (ACGME) for administrative support. Funding Information: The work that produced the Milestones 2.0 was fully funded by the Accreditation Council for Graduate Medical Education. This included travel costs for the working group members. Acknowledgments
PY - 2020/12
Y1 - 2020/12
UR - http://www.scopus.com/inward/record.url?scp=85087721624&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087721624&partnerID=8YFLogxK
U2 - 10.1007/s40596-020-01275-0
DO - 10.1007/s40596-020-01275-0
M3 - Article
C2 - 32643060
AN - SCOPUS:85087721624
SN - 1042-9670
VL - 44
SP - 779
EP - 784
JO - Academic Psychiatry
JF - Academic Psychiatry
IS - 6
ER -